drugset / Trial / NCT00742209

Prevention Study in Adult Patients Suffering From Migraine Headaches

NCT00742209

Phase 2 Completed 526 enrolled XenoPort, Inc. GlaxoSmithKline · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Purpose of the study is to evaluate dose response relationship, efficacy, safety and tolerability of target doses of GSK1838262 compared to placebo in the prophylactic treatment of migraine headache. Once subjects complete the baseline and meet the randomization criteria, they will complete a 5-wk flexible titration period and then enter the 12 week maintenance period.

Timeline

Start
2008-08
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator gabapentin enacarbil Small molecule 1200 mg
Comparator gabapentin enacarbil Small molecule 1800 mg
Comparator gabapentin enacarbil Small molecule 2400 mg
Comparator gabapentin enacarbil Small molecule 3000 mg

Indications